

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 22-K-004

## You asked:

- 1. For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:
  - Aflibercept 1931
  - Bevacizumab 0
  - Brolucizumab <5\*</li>
  - Dexamethasone 50
  - Faricimab 0
  - Ranibizumab Lucentis 8
  - Ranibizumab Ongavia 0
- 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatment listed below, excluding patients who previously had any anti-VEGF therapy
  - Aflibercept 67
  - Bevacizumab 0
  - Brolucizumab 0
  - Dexamethasone 0
  - Faricimab 0
  - Ranibizumab Lucentis 0
  - Ranibizumab Ongavia 0
- \* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This



interest test.		

exemption is absolute and therefore there is no requirement to apply the public